Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 16, 2015, Pages 2523-2529

  Dhanuka, Ida ^a   Simon, James A ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

female sexual distress; female sexual dysfunction; flibanserin; hypoactive sexual desire disorder

Indexed keywords

FLIBANSERIN; BENZIMIDAZOLE DERIVATIVE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ARTICLE; DISTRESS SYNDROME; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; MAXIMUM PLASMA CONCENTRATION; SEXUAL SATISFACTION; ANIMAL; FEMALE; LIBIDO; PHASE 3 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

ANIMALS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; LIBIDO; PREMENOPAUSE; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 84947493549     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.1090426     Document Type: Article

References (24)

1. Carrier M, Khorana A, Zwicker J, et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013;11:1760-5
2. Prandoni P. Venous thromboembolism in 2013: The advent of the novel oral anticoagulants. Nat Rev Cardiol 2014;11:70-2
3. Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: A systematic review and meta-analysis. Chest 2015;147:475-83
4. van Es N, Coppens M, Schulman S, et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014;124:1968-75
5. Günzler C, Berner MM. Efficacy of psychosocial interventions in men and women with sexual dysfunctions-A systematic review of controlled clinical trials. J Sex Med 2012;9:3108-25
6. Wellbutrin (bupropion hydrochloride) tablets Prescribing Information. Research Triangle Park: GlaxoSmithKline
7. Reis S, Abdo C. Benefits and risks of testosterone treatment for hypoactive sexual desire disorder in women: A critical review of studies published in the decades preceding and succeeding the advent of phosphodiesterase type 5 inhibitors. Clinics 2014;69(4):294-303
8. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294(1):91-6
9. AndroGel (testosterone gel) 1% Prescribing Information. AbbVie Inc., Chicago; 2015
10. Parlodel (bromocriptine mesylate) Consumer Medicine Information. Novartis Pharmaceuticals, 2013
11. Low MY, Lin L, Ge X, et al. Isolation and structural elucidation of flibanserin as an adulterant in a health supplement used for female sexual performance enhancement. J Pharm Biomed Anal 2012;57:104-8
12. Borsini F, Evans K, Jason K, et al. Pharmacology of flibanserin. CNS Drug Rev 2002;8(2):117-42
13. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011;8:15-27
14. Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee. FDA Briefing Document. NDA 022526 Flibanserin. Food and Drug Administration, Washington DC; 2015
15. Katz M, DeRogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013;10:1807-15
16. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804
17. Derogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 2012;9(4):1074-85
18. Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014;21(6):633-40
19. ADDYI (flibanserin) Prescribing Information. Sprout Pharmaceuticals Inc., Raleigh, NC; 2015
20. Risk Evaluation and Mitigation Strategy (REMS). NDA 022526 AddyiTM (flibanserin). Food and Drug Administration, Washington DC; 2015
21. Thorp J Jr, Palacios S, Symons J, et al. Improving prospects for treating hypoactive sexual desire disorder (HSDD): development status of flibanserin. BJOG 2014;121:1328-32
22. Clayton AH, DeRogatis LR, Rosen RC, et al. Intended or unintended consequences? the likely implications of raising the bar for sexual dysfunction diagnosis in the proposed DSM-V revisions: 1. for women with incomplete loss of desire or sexual receptivity. J Sex Med 2012;9:2027-39
23. Meston CM. Validation of the female sexual function index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther 2003;29(1):39-46
24. West SL, D'Aloisio AA, Agans RP, et al. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US Women. Arch Intern Med 2008;168:1441-9